

Department of Medicine
Medical Grand Rounds

DATE: 8/21/2020
LOCATION: Virtually Via Zoom from the ERC
TIME: 12:00 – 1:00 PM
TITLE: “Lung Cancer for the Internist”
Speaker: Drs. Ryan Gentzler and Rick Hall

For CME and MOC Credits as well as Instruction on How to Claim Credit please go to:
<https://med.virginia.edu/cme/learning/uvarss/medgrmoc/>

LEARNING OBJECTIVES:

1. Identify the appropriate patient for lung cancer screening
2. Describe the impact of targeted therapy and immunotherapy on lung cancer survival
3. Recognize at least 2 distinct molecular subtypes of lung adenocarcinoma

QUESTIONS:

1. Which of the following screening imaging modalities has been proven to reduce lung cancer related mortality?
 - a) CXR
 - b) CT Chest
 - c) PET/CT
 - d) None of the Above
2. Which of the following thoracic malignancies does not have an FDA approved indication for the use of an immunotherapy agent?
 - a) Thymoma
 - b) Small Cell Lung Cancer
 - c) Non-Small cell Lung Cancer, adenocarcinoma
 - d) Non-small cell lung cancer, squamous cell carcinoma
3. Which of the following mutations in lung adenocarcinomas have FDA approved molecularly targeted therapies available for the treatment of newly diagnosed, stage IV disease?
 - a) EGFR
 - b) ALK
 - c) RET
 - d) All of the Above
- 4) True or False – The median overall survival for patients with stage IV, *ALK* rearranged NSCLC exceeds 5 years.
- 5) True or False – There are 7 distinct molecular subtypes of lung adenocarcinoma for which there is an FDA approved targeted therapy.

DISCLOSURES: Dr. Ryan Gentzler is on the Advisory Committee/Board of Pfizer.

Dr. Richard Hall is an industry funded research/investigator for Merck and is on the Advisory Committee/Board for Pfizer & AstraZeneca.